<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Durrington, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francesco Cosentino, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinical dyslipidemia includes, but is not limited to, patients with abnormal levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, or lipoprotein(a). An abnormal level of each of these is the result of one or more genetic abnormalities or secondary to some underlying disease or environmental factors [<a href="#rid1">1</a>]. </p><p>One definition of dyslipidemia is total cholesterol, LDL-C, triglyceride, or lipoprotein(a) levels above the 90th percentile or high-density lipoprotein cholesterol or apoA-1 levels below the 10th percentile for the general population  (<a class="graphic graphic_table graphicRef71803" href="/z/d/graphic/71803.html" rel="external">table 1</a>). </p><p>Elevation of LDL-C is common in the general population. Most of these individuals have one or more genetic abnormalities rather than a secondary cause (such as liver or kidney disease) (see  <a class="medical medical_review" href="/z/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a>). For individuals with LDL-C above 190 mg/dL, the genetic defects that lead to familial hypercholesterolemia (FH) are the most common underlying cause (see  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a>). This topic will discuss non-FH causes of elevated LDL-C.</p><p>General treatment guidelines for elevated LDL-C and possible indications for the therapy of other dyslipidemias, such as low serum high-density lipoprotein cholesterol, hypertriglyceridemia, and elevated serum lipoprotein(a), are discussed in other topic reviews. (See  <a class="medical medical_review" href="/z/d/html/4560.html" rel="external">"HDL cholesterol: Clinical aspects of abnormal values"</a> and  <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">"Lipoprotein(a)"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.) </p><p>The approach to children with dyslipidemia is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a> and  <a class="medical medical_review" href="/z/d/html/5753.html" rel="external">"Overview of the management of the child or adolescent at risk for atherosclerosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE OF LIPID ABNORMALITIES</span><span class="headingEndMark"> — </span>The prevalence of one or more abnormal lipid fractions varies with the population being studied. It is highest in populations of patients with premature coronary heart disease (CHD), which can be defined as occurring before 55 to 60 years of age in men and before 65 years in women. In this setting, the prevalence of dyslipidemia is as high as 75 to 85 percent compared with approximately 40 to 48 percent in age-matched controls without CHD  (<a class="graphic graphic_figure graphicRef59944" href="/z/d/graphic/59944.html" rel="external">figure 1</a>) [<a href="#rid2">2,3</a>]. The lipid abnormality is often familial. In one study, for example, 54 percent of all patients with premature CHD (and 70 percent of those with a lipid abnormality) had a familial disorder [<a href="#rid2">2</a>]. In the great majority of patients, inheritance is polygenic and the expression of dyslipidemia is strongly influenced by factors such as obesity (particularly central obesity) and the saturated fat and cholesterol content of the diet. </p><p>In nations with low rates of obesity and where saturated fat intake is low, both the incidence of CHD and the prevalence of dyslipidemia are low compared with North America and Europe. </p><p class="headingAnchor" id="H3"><span class="h1">GENETICS OF ELEVATED LDL-C</span><span class="headingEndMark"> — </span>The terminology surrounding the hereditary disorders of low-density lipoprotein cholesterol (LDL-C) metabolism can be confusing. Individual patients may have one (monogenic) or more (polygenic) genetic defects that lead to a particular phenotype. (See <a class="local">'Polygenic hypercholesterolemia'</a> below.) </p><p>The clinical syndrome of familial hypercholesterolemia (FH) is the leading clinical phenotype resulting from monogenic, usually dominantly inherited defects in LDL catabolism. As FH has been well studied and there is an extensive literature, it is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a>.)</p><p>Familial combined hyperlipidemia and polygenic hypercholesterolemia are examples of syndromes with polygenic inheritance; there is overlap between these two types of hypercholesterolemia. In patients in with an isolated increase in LDL-C that is not high enough to carry out exhaustive cascade family screening for monogenic FH, these two are harder to distinguish. Therefore, most patients will be classified as having a mixed hyperlipidemia.</p><p class="headingAnchor" id="H16"><span class="h1">FAMILIAL COMBINED HYPERLIPIDEMIA</span><span class="headingEndMark"> — </span>Familial combined hyperlipidemia (FCHL) is a common genetic lipid disorder (1 to 2 percent of the population). Patients present with elevated levels of plasma total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and apolipoprotein (apo) B. Premature atherosclerotic cardiovascular disease (ASCVD) is not uncommon. There is overlap with metabolic syndrome (see  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>) and diabetic dyslipidemia. When not initially present, there is an increased future likelihood of impaired glucose tolerance or type 2 diabetes. </p><p class="headingAnchor" id="H3953573507"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>FCHL is a complex, polygenic disorder in which gene variants potentially causing elevations of VLDL and of LDL run in the same families. Screening of relatives reveals some with an increase in both cholesterol and triglycerides, some with increased cholesterol but normal triglycerides, some with principally hypertriglyceridemia (often mild, but occasionally type V), and others in whom there is little, if any, dyslipidemia. </p><p>The phenotype is usually determined by interaction of multiple susceptibility genes and the environment [<a href="#rid4">4,5</a>]. Coinheritance of two or more gene variants potentially affecting lipoprotein metabolism are generally required for the expression of FCHL.</p><p>In many cases, FCHL is caused by overproduction of hepatically-derived apoB-100 associated with very low-density lipoprotein (VLDL) [<a href="#rid4">4</a>]. In these cases, there is an autosomal dominant pattern of inheritance. ApoB levels are strongly correlated with LDL phenotype B in FCHL families [<a href="#rid6">6,7</a>]; LDL phenotype B levels are inherited as a Mendelian trait that is distinct from the apoB genotype [<a href="#rid6">6</a>]. LDL phenotype B is associated with increased serum concentrations of apoB and triglycerides, reduced serum high-density lipoprotein (HDL)  (<a class="graphic graphic_figure graphicRef63857" href="/z/d/graphic/63857.html" rel="external">figure 2</a>) [<a href="#rid8">8</a>], and a threefold increase in risk of CHD [<a href="#rid9">9</a>]. LDL phenotype A is associated with large buoyant LDL particles; in comparison, phenotype B is characterized by small, dense LDL particles. (See <a class="local">'Small dense LDL (LDL phenotype B)'</a> below.)</p><p>A study of 31 extended Finnish FCHL families suggested a novel locus on chromosome 1q21-q23 [<a href="#rid10">10</a>]. A follow-up study that included an additional 29 families found that FCHL was linked and associated with the gene-encoding upstream transcription factor 1 (USF1); USF1 encodes a transcription factor known to regulate several genes involved in glucose and lipoprotein metabolism [<a href="#rid11">11</a>].</p><p>The phenotypic heterogeneity derives from variations in LDL subclass pattern and an associated impairment in lipoprotein lipase (mass and activity) in one-third of cases [<a href="#rid12">12</a>]. Those patients with abnormal lipoprotein lipase (LPL) function have higher levels of triglycerides (due to decreased clearance) and lower levels of HDL-C (due to reduced production from triglyceride-depleted VLDL remnants) than those with normal LPL activity. In at least some patients, a mutation in the LPL gene is responsible [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p class="headingAnchor" id="H343827691"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The clinical manifestations include premature CHD (particularly in patients with concurrent hypertriglyceridemia), xanthelasma (in 10 percent of cases), and obesity [<a href="#rid14">14</a>]. Coexisting diabetes mellitus or impaired glucose tolerance is more common in patients who also have hypertriglyceridemia.</p><p>Obesity is common in FCHL, but some patients in whom the genetic components are particularly penetrant may be lean.</p><p>One study of 63 families with FCHL found that, after adjustment for baseline covariates, 20-year cardiovascular disease mortality was increased among siblings and offspring in FCHL compared with spouse control subjects (relative risk 1.7) [<a href="#rid15">15</a>]. Baseline triglyceride concentrations were not independently associated with an increased risk.</p><p class="headingAnchor" id="H3908705493"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The pathophysiological mechanism underlying FCHL is believed to be hepatic overproduction of apoB-100-containing lipoprotein particles (ie, VLDL and LDL), resulting in increased plasma total cholesterol, triglycerides, and apoB levels [<a href="#rid14">14,16,17</a>]. In addition, lower levels of HDL-cholesterol and increased amounts of small dense LDL and remnant lipoprotein particles have been observed in patients with FCHL. </p><p class="headingAnchor" id="H1792944618"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>FCHL is diagnosed in patients with a family history of premature CHD and whose apoB concentration is &gt;120 mg/dL in combination with either elevations in both LDL-C and triglycerides or either elevated LDL-Col or triglycerides [<a href="#rid16">16,17</a>]. </p><p>Because FCHL is phenotypically heterogeneous, and total cholesterol and triglyceride levels may vary within an affected individual over time [<a href="#rid18">18</a>], the diagnosis of this disorder or the possible variant hyperapobetalipoproteinemia requires family data. The presence of one of these two conditions is suggested by an LDL-to-apoB ratio of less than 1.2 (normal value &gt;1.4).</p><p>Sometimes, familial dysbetalipoproteinemia (FDB; type III hyperlipoproteinemia) is the differential diagnosis (see  <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Clinical classification of dyslipidemias'</a>). The simplest way to distinguish this from FCHL is to measure apoB, which is low in relation to triglycerides and cholesterol in FDB.</p><p class="headingAnchor" id="H17"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The first-line treatment of FCHL is a statin, irrespective of whether or not triglyceride levels are elevated [<a href="#rid19">19</a>], which is effective therapy for lowering apoB levels [<a href="#rid20">20</a>]. The potency and dose of statin should be chosen with the aim of achieving LDL-C &lt;100 mg/dL in primary prevention and &lt;70 mg/dL in secondary prevention. High intensity statins (<a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 80 mg daily and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> 40 mg daily) lower triglycerides by 43 percent in patients with triglycerides as high as 800 to 850 mg/dL [<a href="#rid21">21,22</a>].</p><p>The main reason for introducing statins before fibrates in hypertriglyceridemic dyslipidemias is not that they are better at lowering triglycerides, but because of the randomized clinical trial evidence that they are safe and that they decrease cardiovascular disease risk and mortality [<a href="#rid23">23</a>]. Similar evidence does not exist for fibrates. </p><p>It should be kept in mind that when triglyceride concentrations are high (≥400 mg/dL), the laboratory may be unable to provide accurate LDL-C measurements; non-HDL cholesterol targets should be used. (See  <a class="medical medical_review" href="/z/d/html/4556.html" rel="external">"Measurement of blood lipids and lipoproteins", section on 'Non-HDL cholesterol'</a>.)</p><p>If the LDL-C or non-HDL-C therapeutic goals are not reached, addition of <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a> can be considered. Generally, bile acid sequestrants are avoided in hypertriglyceridemia, which they may exacerbate. The exception is <a class="drug drug_general" data-topicid="8954" href="/z/d/drug information/8954.html" rel="external">colesevelam</a>, which, if administered to achieve greater lowering of LDL or non-HDL-C, has a lesser adverse effect on triglycerides in studies that included an upper triglyceride limit of 300 mg/dL, while reducing the total atherogenic burden of apoB-containing lipoproteins, and it improves glucose intolerance [<a href="#rid24">24</a>].</p><p>Often, triglycerides will remain elevated after statin treatment (with or without <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a>). The decision to add a drug to lower triglycerides is a difficult one. For many years, fibrate drugs and <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a> were employed for this purpose, but randomized clinical trial evidence does not support any effect of these drugs in reducing cardiovascular disease events or improving overall survival [<a href="#rid25">25</a>]. Subgroup analysis does suggest that fibrate monotherapy can decrease the likelihood of CHD events in hypertriglyceridemia. However, it is uncertain that this is the case in patients also receiving statin treatment. As the benefit is uncertain, we suggest referring statin-treated patients with significant residual hypertriglyceridemia to a lipid specialist for consideration of additional therapy. An alternative is to consider adding a highly purified omega-3 fatty acid preparation to the statin treatment to decrease triglycerides further. Evidence, although conflicted, does suggest improved survival from taking highly purified omega-3s in people with CHD. Furthermore, the risk of myopathy is not increased when omega-fatty acid is used in combination with statin treatment as it is with fibrates and niacin.</p><p>Glucose intolerance is common in hypertriglyceridemia and when type 2 diabetes is discovered in hypertriglyceridemia, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> should be considered as initial treatment, because of its action in mitigating weight gain and improving lipid levels [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H19"><span class="h1">POLYGENIC HYPERCHOLESTEROLEMIA</span><span class="headingEndMark"> — </span>Familial hypercholesterolemia (FH), which is a monogenic disorder, is the most common inherited disorder of LDL catabolism. It is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a>.)</p><p>Many patients with the FH clinical phenotype, but without a single mutation of sufficient pathogenicity to produce it, will have multiple (polygenic) gene variants, each of which makes a small independent contribution to a significantly elevated LDL-C [<a href="#rid27">27</a>]. These patients are said to have polygenic hypercholesterolemia. Some of these individuals express marked hypercholesterolemia when only two or three penetrant gene variants combine, whereas others may require the combination of greater numbers of less penetrant ones. The former type of polygenic hypercholesterolemia mimicking monogenic FH is termed "oligogenic FH." It is possible to devise a "gene score" based on the number and likelihood of these variants to contribute to high LDL-C. (See <a class="local">'Testing'</a> below.)</p><p>Generally, polygenic hypercholesterolemia has less marked elevations in LDL-C (particularly in childhood and adolescence) than monogenic FH and does not carry the high risk of cardiovascular disease (CVD) in people aged less than 40 years [<a href="#rid28">28</a>]. Stated another way, a higher proportion of those with high LDL-C at a young age will have it as a result of FH rather than polygenic hypercholesterolemia [<a href="#rid29">29</a>]. </p><p>Whole genome sequencing has been used to develop polygenic scores that quantify DNA variants that contribute to a risk factor. The contribution of polygenic cholesterol scores to early-onset myocardial infarction (&lt;55 years of age) was investigated in an analysis of 2081 patients hospitalized with a myocardial infarction from four racial subgroups and 3761 population-based controls. Among patients with early-onset myocardial infarction, 17.3 percent carried a high polygenic cholesterol score, defined as the upper fifth percentile, versus 5 percent of the control population [<a href="#rid30">30</a>]. The mean LDL-C in patients with versus without a high polygenic risk score was 132 versus 122 mg/dL. A high polygenic score was more common among patients with early-onset myocardial infarction. The multivariate adjusted risk of early-onset myocardial infarction varied among racial groups with odds ratios of 5.09 in White Americans, 3.38 in Hispanic Americans, 3.33 in Asian Americans, and 2.02 in Black Americans. The 0.2 percent of patients with a high polygenic risk score and confirmed monogenic mutation related to familial hypercholesterolemia had higher mean LDL-C levels than those with only a familial hypercholesterolemia monogenic mutation (LDL-C 235 versus 202 mg/dL). Thus, polygenes may contribute to variability in LDL-C levels seen in patients with the same monogenic mutation.</p><p class="headingAnchor" id="H20"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The genetics of polygenic hypercholesterolemia are poorly understood but multiple abnormalities in LDL metabolism are involved [<a href="#rid31">31</a>]. </p><p>These abnormalities in LDL metabolism include mild defects in the LDL receptor, defective apoB-100, increased synthesis of apoB, and the presence of the apoE4 phenotype. ApoE is required for receptor-mediated clearance of chylomicron and very low-density lipoprotein remnants from the circulation. ApoE4 has a higher affinity for the LDL receptor than the other apoE isoforms. The enhanced lipid binding leads, via negative feedback, to downregulation of LDL receptor synthesis and consequently a secondary rise in LDL-C levels. </p><p>A genetic study of over 600 patients with clinical FH and 3020 controls attempted to distinguish patients with polygenic and monogenic FH by genotyping for the three known genetic causes of FH (see <a class="local">'Genetics of elevated LDL-C'</a> above) and 12 common LDL-C raising single-nucleotide polymorphisms [<a href="#rid32">32</a>]. In this study, only about 50 percent of patients with clinical FH had monogenic FH; of these, many had multiple minor cholesterol-elevating alleles. Multiple genetic mutations were often found in those labeled as having a polygenic cause (none of the three known genetic causes found).</p><p>In a study of over 20,000 coronary artery disease-free individuals, the prevalence of LDL-C ≥190 mg/dL was 6.7 percent [<a href="#rid33">33</a>]. Using whole exam sequencing, 1.7 percent of these had an FH mutation. In patients with very high LDL-C levels (≥190 mg/dL) and no FH mutation compared with controls (LDL-C &lt;130 mg/dL), the risk of coronary artery disease was sixfold higher (odds ratio: 6.0, 95% CI 5.2-6.9). However, in patients with LDL-C ≥190 mg/dL and an FH mutation, the risk was 22-fold higher (odds ratio 22.3; 95% CI 10.7-53.2). </p><p>Multiple studies and reviews have evaluated the relationship between apoE genotypes (particularly the apoE4 allele) and both LDL-C and the incidence of CHD [<a href="#rid34">34-36</a>]. However, these reports may have been underpowered to detect the true relationship and also subject to publication bias [<a href="#rid37">37</a>].</p><p>The largest meta-analysis of the impact of the presence of the apoE allele on LDL-C levels and CHD risk came to the following conclusions using the E3/E3 genotype as the reference [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>There was an approximately linear relationship of apoE genotypes (when ordered E2/E2, E2/E3, E3/E3, E3/E4, and E4/E4) with LDL-C. There was a weakly inverse relationship of these genotypes with high-density lipoprotein cholesterol (HDL-C) level and a non-linear relationship with triglycerides, with the E3/E3 genotype having the lowest triglyceride levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was an approximately linear relationship of apoE genotypes (when ordered E2/E2, E2/E3, E3/E3, E3/E4, and E4/E4) with CHD risk. Compared with the apoE3/E3 individual, the odds ratio for CHD was 0.8 (95% CI, 0.70-0.90) in E2 carriers and 1.06 (95% CI, 0.99-1.13) in E4 carriers.</p><p></p><p class="headingAnchor" id="H1743914437"><span class="h3">Testing</span><span class="headingEndMark"> — </span>In polygenic hypercholesterolemia, it may be important to screen relatives for elevated cholesterol even though an FH mutation is not present. Genes in combinations leading to severe hypercholesterolemia often occur in other family members and the proband should be advised to ask all his/her first-degree relatives to get a cholesterol check.</p><p>Until genetic testing has been shown to improve clinical outcomes in individuals with one (eg, FH) or more (eg, polygenic hypercholesterolemia) genetic mutations that might lead to a significantly elevated LDL-C, we do not perform routine testing, even after an adverse event such as myocardial infarction. </p><p>Without genetic testing, it can be difficult to differentiate polygenic hypercholesterolemia from FH. Studies have identified minor LDL-C-elevating alleles that contribute to the familial basis for this disorder [<a href="#rid27">27</a>]. Similar to patients with monogenic FH, these patients have familial aggregation of moderate hypercholesterolemia and the premature onset of coronary heart disease. The lipid profile shows an elevated LDL-C level, and (usually) a normal triglyceride level; tendon xanthoma are not seen  (<a class="graphic graphic_table graphicRef66747" href="/z/d/graphic/66747.html" rel="external">table 2</a>). As age advances, cardiovascular disease risk in patients with severe polygenic hypercholesterolemia or possible FH with no single causal gene identified carries a similar risk to monogenic FH. (See  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview", section on 'Genetic considerations'</a>.)</p><p>When resources permit and heterozygous FH is suspected on clinical grounds we do, however, recommend cascade family screening, ideally establishing the DNA mutation in one family member and then seeking this in others. The aim is to identify affected family members at an early age when we believe treatment can improve clinical outcomes. (See  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children", section on 'Testing family members'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Therapy in polygenic hypercholesterolemia usually begins with a statin; <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a>, a bile acid sequestrant, PCSK9 inhibitor, or nicotinic acid are alternatives in patients who cannot tolerate a statin [<a href="#rid38">38</a>]. The 4S trial, which followed 966 survivors of a myocardial infarction for 5.5 years, found that those with the apoE4 allele had a nearly twofold increased risk of dying compared with other patients; this excess mortality was abolished by treatment with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> [<a href="#rid39">39</a>]. </p><p>Further lowering of LDL-C may be accomplished by combining a statin with <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a>. Low doses of nicotinic acid (1 to 1.5 g/day) will also raise HDL-C, a desirable effect in patients with hypercholesterolemia and low HDL-C.</p><p class="headingAnchor" id="H22"><span class="h1">SMALL DENSE LDL (LDL PHENOTYPE B)</span><span class="headingEndMark"> — </span>Low-density lipoprotein (LDL) particles are heterogeneous in size, density, and composition [<a href="#rid40">40</a>]. Individuals can be classified according to their predominant LDL size into one of three phenotypic patterns on gradient gel electrophoresis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenotype pattern A</strong> – Large particle size, ≥26.3 nm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenotype pattern B</strong> – Small particle size, &lt;25.8 nm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenotype pattern I</strong> – Intermediate particle size (mixed distribution), 25.8 to 26.3 nm in diameter</p><p></p><p>Small, dense LDL particles (phenotype B) are cholesterol-depleted LDL particles that are associated with increased serum concentrations of triglycerides, reduced serum high density-lipoprotein cholesterol (HDL-C) levels  (<a class="graphic graphic_figure graphicRef63857" href="/z/d/graphic/63857.html" rel="external">figure 2</a>), and an increased risk of coronary heart disease (CHD) that presumably derives from the excess total LDL particles. The risk of cardiovascular disease associated with small, dense LDL is increased only when the total LDL particle concentration is elevated [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H23"><span class="h2">Determinants</span><span class="headingEndMark"> — </span>LDL phenotype B levels are in part genetically determined [<a href="#rid6">6</a>]. Studies of monozygotic and dizygotic women twin pairs suggest that one-third to one-half of the variation in LDL particle diameter can be attributed to genetic factors [<a href="#rid42">42</a>]. One gene that may contribute is the gene for cholesteryl ester transfer protein (CETP), which plays a central role in reverse cholesterol transport [<a href="#rid43">43</a>]. CETP moves cholesterol from peripheral tissues to the liver by transferring cholesteryl ester from HDL-C to apoB-containing lipoproteins with triglyceride transfer in the opposite direction. Increased CETP activity may be proatherogenic and is associated with LDL phenotype B [<a href="#rid43">43</a>].</p><p>LDL phenotype B levels are also influenced by acquired conditions. As an example, they are associated with obesity, type 2 diabetes, and the manifestations of the acquired insulin resistance syndrome such as hypertriglyceridemia, hyperinsulinemia, increased waist-to-hip ratio, low levels of large HDL particles, and systolic hypertension [<a href="#rid44">44,45</a>].</p><p>High hepatic lipase activity hydrolyzes triglyceride in triglyceride-enriched LDL and triglyceride-enriched HDL particles, which results in small, dense LDL particles and larger HDL particles (HDL-S [HDL3 cholesterol by ultracentrifugation]), and increased HDL particle size. Interventions that alter hepatic lipase activity can reduce the concentration of small, dense LDL particles. Among patients in the FATS trial with a personal and family history of CHD and apoB levels ≥125 mg/dL (3.3 mmol/L), intensive lipid-lowering therapy with lovastatin-colestipol or niacin-colestipol produced a significant reduction in hepatic lipase activity and an increase in large, buoyant LDL particles [<a href="#rid46">46</a>]. These changes were associated with a significant improvement in disease severity; in a multivariate analysis, an increase in LDL buoyancy was most strongly associated with regression of CHD, accounting for 37 percent of the variance of change in coronary stenosis. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>Hepatic lipase deficiency should be suspected when the HDL-C is unexpectedly high. Hepatic lipase hydrolyses fatty acyl chains of phospholipids, monoacylglycerols, diacylglycerols, and triacyl‐glycerols are associated with HDL and other lipoproteins [<a href="#rid47">47</a>]. Rare, loss‐of‐function variants can cause of deficiency of hepatic lipase, resulting in a two- to threefold increased HDL‐C levels [<a href="#rid48">48</a>]. In some susceptible families, hepatic lipase deficiency can result in increased risk of ASCVD. This occurs from elevations in potentially proatherogenic apoB-containing lipoproteins [<a href="#rid48">48</a>]. </p><p>The effect of hepatic lipase may be related to a polymorphism in the hepatic lipase gene promoter, the most common being a C to T substitution. The presence of a C allele is associated with higher hepatic lipase activity; smaller, denser, and more atherogenic LDL particles; and lower serum HDL-C [<a href="#rid49">49</a>].</p><p>The angiographic improvement with lipid lowering is most prominent in subjects with small, dense LDL and lower serum HDL-C, suggesting that hepatic lipase polymorphism might have predictive value [<a href="#rid50">50</a>]. This hypothesis was evaluated in a study of 49 men with established coronary disease and dyslipidemia; patients with the CC genotype had the greatest decrease in hepatic lipase activity, improvement in LDL density, and regression in coronary atherosclerosis (96 versus 60 and 0 percent for TC and TT genotypes) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Increase in coronary risk</span><span class="headingEndMark"> — </span>Based on the high residual cardiovascular risk in metabolic syndrome and type 2 diabetes patients who achieve current recommended LDL-C targets on statin therapy, we agree with the American Diabetes Association/American College of Cardiology Foundation-issued consensus statement recommending measurement of apoB (or LDL-P concentration) in patients at high cardiometabolic risk, as well as treatment of high levels of apoB or LDL-P concentration, after therapeutic interventions have been initiated for treatment of LDL-C and non-HDL-C [<a href="#rid52">52</a>]. Treatment targets for LDL-C/non-HDL-C/LDL-P/apoB are presented in the following table  (<a class="graphic graphic_table graphicRef52294" href="/z/d/graphic/52294.html" rel="external">table 3</a>). </p><p>Small, dense LDL particles have been consistently associated with CHD in case-control studies [<a href="#rid9">9,53-57</a>]; however, these studies are limited because most studies did not control for the total LDL particle or apoB concentration. The Stanford Five-City Project evaluated the association between LDL particle diameter with incident fatal and nonfatal myocardial infarction (MI) in a nested case-control study [<a href="#rid56">56</a>]. The study included 124 case-control pairs (90 pairs of men and 34 pairs of women). The patients with MI had a smaller LDL size (mean 26.17 versus 26.68 nm, p&lt;0.001) and there was a graded association across quintiles of LDL size. Small LDL size was a stronger independent predictor of CHD than all other parameters except for the total cholesterol-to-HDL-C ratio.</p><p>The Physicians' Health Study used a nested case-control study to evaluate whether small, dense LDL particles and nonfasting triglyceride levels were independent predictors for MI in men [<a href="#rid57">57</a>]. The study group included 266 cases and 308 controls that were matched for age and smoking status. The cases had a significantly lower average LDL diameter (25.6 versus 25.9 nm, p&lt;0.001) and higher serum triglycerides. Small, dense LDL was associated with higher triglyceride and lower HDL-C levels, and LDL diameter was not an independent risk factor after adjustment for the high triglyceride levels. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p>It may be possible to refine the risk associated with small, dense LDL particle size. In a prospective study of over 2000 men, for example, the ability to predict CHD was improved by measuring the cholesterol concentration in the small LDL particles [<a href="#rid58">58</a>].</p><p>In addition to determining coronary risk, LDL particle size is also an important predictor of the response to risk-factor reduction. The Stanford Coronary Risk Intervention Project (SCRIP) was a four-year angiographic trial of multifactorial risk reduction versus usual care [<a href="#rid50">50</a>]. LDL particles were classified by density into a "buoyant" (density &lt;1.0378 g/mL) or "dense" mode (density &gt;1.0378 g/mL). Cholesterol-lowering therapy produced a significant treatment benefit only in the dense-mode subjects. As noted above, an improvement in LDL density and regression of atherosclerosis appears to be most prominent in patients with the CC genotype for the hepatic lipase gene promoter [<a href="#rid51">51</a>].</p><p>The Women's Health Study examined the associations of small, dense LDL versus large buoyant LDL in multivariate models that controlled for the total LDL particle concentration [<a href="#rid41">41</a>]. In this analysis, small, dense LDL was not as closely associated with a significantly higher risk of cardiovascular events as large, buoyant LDL after adjusting for the total LDL particle concentration. </p><p>At any level of LDL-C, individuals with an increased number of small LDL particles have higher LDL particle (LDL-P) concentrations. In multivariate models, LDL-P size is not related to increased cardiovascular risk after adjustment for LDL-P concentration or its surrogate measure apolipoprotein B (apoB) [<a href="#rid41">41,59</a>]. Thus, LDL size represents part of the pattern of atherogenic dyslipidemia, and it is not a specific therapeutic target. In individuals with disorders of insulin resistance (obesity, metabolic syndrome, type 2 diabetes), LDL-C under-represents cardiovascular risk due to the discordance between LDL-C and LDL-P [<a href="#rid59">59,60</a>]. Thus, LDL-P, or its surrogate measure apoB, has been considered a target of therapy, as this measure is associated with a twofold higher risk of cardiovascular disease events than LDL-C. Moreover, in statin-treated patients, apoB levels are more strongly associated with residual cardiovascular risk than LDL-C [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Mechanisms of increased atherogenicity</span><span class="headingEndMark"> — </span>The atherogenic potential of small LDL particles has been related to both direct and indirect mechanisms. The direct mechanisms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced oxidative susceptibility [<a href="#rid62">62,63</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced clearance by LDL receptors in the liver with increased LDL receptor-independent binding in the arterial wall [<a href="#rid64">64,65</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelial dysfunction that is independent of the concentrations of other lipids [<a href="#rid66">66</a>]</p><p></p><p>These factors may interact. Less avid binding to the LDL receptor prolongs the half-life of small, dense LDL in the circulation, increasing the likelihood that they will undergo oxidative modification and subsequent uptake by the macrophage scavenger receptors [<a href="#rid65">65</a>].</p><p>Indirect associations between small, dense LDL and atherogenic risk include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inverse relationship with HDL-C  (<a class="graphic graphic_figure graphicRef63857" href="/z/d/graphic/63857.html" rel="external">figure 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Marker for accumulation of atherogenic triglyceride remnant particles [<a href="#rid67">67</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance [<a href="#rid44">44</a>]</p><p></p><p class="headingAnchor" id="H26"><span class="h1">LOW LDL-CHOLESTEROL LEVELS</span><span class="headingEndMark"> — </span>Two genetic disorders causing extremely low levels of low-density lipoprotein-cholesterol have been identified. These two, "abetalipoproteinemia" and "hypobetalipoproteinemia," are referred to as "familial hypobetalipoproteinemia." These disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation"</a>.)</p><p class="headingAnchor" id="H2170900092"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>As a result of the frequency of familial disease and the associated risk, screening lipid analysis is recommended for first-degree relatives of patients with myocardial infarction (particularly if premature). Screening begins with a standard lipid profile; if this is normal, further testing should be considered depending on the abnormalities identified in the affected family member, such as the measurement of lipoprotein(a) and apolipoproteins B and A-I; approximately 25 percent of patients with premature coronary heart disease and a normal standard profile will have an abnormality in one of these factors. A larger discussion of screening for dyslipidemia is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.)</p><p class="headingAnchor" id="H183315699"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Patients who have persistently elevated LDL-C or non HDL-C on maximum tolerated statins should be referred to a lipid specialist.</p><p class="headingAnchor" id="H3234803886"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110734.html" rel="external">"Society guideline links: Lipid disorders and atherosclerosis in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109532.html" rel="external">"Society guideline links: Lipid disorders in adults"</a>.)</p><p class="headingAnchor" id="H451294160"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Elevation of low-density lipoprotein cholesterol (LDL-C) is common in the general population. Most individuals with elevated LDL-C have one or more genetic abnormalities rather than a secondary cause (such as liver or kidney disease). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics of elevated LDL-C </strong>– The clinical syndrome of familial hypercholesterolemia is the leading clinical phenotype resulting from inheritance of a monogenic abnormality in LDL metabolism. Familial combined hyperlipidemia and polygenic hypercholesterolemia are examples of syndromes with polygenic inheritance. (See <a class="local">'Genetics of elevated LDL-C'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial combined hyperlipidemia (FCHL) </strong>– This is a relatively common lipid disorder. Statins are generally the first drug added to treat FCHL. (See <a class="local">'Familial combined hyperlipidemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polygenic hypercholesterolemia </strong>– The genetics of polygenic hypercholesterolemia are poorly understood but multiple abnormalities in LDL metabolism are likely involved. Statins are generally the first drug added to treat polygenic hypercholesterolemia. (See <a class="local">'Polygenic hypercholesterolemia'</a> above.) </p><p></p><p class="headingAnchor" id="H3579226142"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Sarah D. de Ferranti for her past contributions as an author to prior versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Durrington P. Dyslipidaemia. Lancet 2003; 362:717.</a></li><li><a class="nounderline abstract_t">Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.</a></li><li><a class="nounderline abstract_t">Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.</a></li><li><a class="nounderline abstract_t">Venkatesan S, Cullen P, Pacy P, et al. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:1110.</a></li><li><a class="nounderline abstract_t">Brouwers MC, van Greevenbroek MM, Troutt JS, et al. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia. Clin Sci (Lond) 2011; 121:397.</a></li><li><a class="nounderline abstract_t">Jarvik GP, Brunzell JD, Austin MA, et al. Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 1994; 14:1687.</a></li><li><a class="nounderline abstract_t">Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34:295.</a></li><li><a class="nounderline abstract_t">Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495.</a></li><li><a class="nounderline abstract_t">Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917.</a></li><li><a class="nounderline abstract_t">Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998; 18:369.</a></li><li><a class="nounderline abstract_t">Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36:371.</a></li><li><a class="nounderline abstract_t">Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992; 12:1176.</a></li><li><a class="nounderline abstract_t">Yang WS, Nevin DN, Peng R, et al. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci U S A 1995; 92:4462.</a></li><li><a class="nounderline abstract_t">Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged &lt; or = 50 years) and women (&lt; or = 60 years) with coronary artery disease. Am J Cardiol 1993; 71:631.</a></li><li><a class="nounderline abstract_t">Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101:2777.</a></li><li><a class="nounderline abstract_t">Veerkamp MJ, de Graaf J, Bredie SJ, et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22:274.</a></li><li><a class="nounderline abstract_t">Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290:140.</a></li><li><a class="nounderline abstract_t">Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109:2980.</a></li><li><a class="nounderline abstract_t">Schonfeld G, Aguilar-Salina C, Elias N. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Am J Cardiol 1998; 81:43B.</a></li><li><a class="nounderline abstract_t">Myerson M, Ngai C, Jones J, et al. Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res 2005; 46:2735.</a></li><li><a class="nounderline abstract_t">Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004; 15:115.</a></li><li><a class="nounderline abstract_t">Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128.</a></li><li><a class="nounderline abstract_t">Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2009; 204:342.</a></li><li><a class="nounderline abstract_t">Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:427.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.</a></li><li><a class="nounderline abstract_t">Wang J, Dron JS, Ban MR, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arterioscler Thromb Vasc Biol 2016; 36:2439.</a></li><li><a class="nounderline abstract_t">Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142:105.</a></li><li><a class="nounderline abstract_t">Wald DS, Bestwick JP, Morris JK, et al. Child-Parent Familial Hypercholesterolemia Screening in Primary Care. N Engl J Med 2016; 375:1628.</a></li><li><a class="nounderline abstract_t">Khera AV, Chaffin M, Zekavat SM, et al. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. Circulation 2019; 139:1593.</a></li><li><a class="nounderline abstract_t">Grundy SM. George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. Arterioscler Thromb 1991; 11:1619.</a></li><li><a class="nounderline abstract_t">Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293.</a></li><li><a class="nounderline abstract_t">Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 2016; 67:2578.</a></li><li><a class="nounderline abstract_t">Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120:1026.</a></li><li><a class="nounderline abstract_t">Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272:1666.</a></li><li><a class="nounderline abstract_t">Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, et al. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2000; 35:1192.</a></li><li><a class="nounderline abstract_t">Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298:1300.</a></li><li><a class="nounderline abstract_t">Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.</a></li><li><a class="nounderline abstract_t">Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101:1366.</a></li><li><a class="nounderline abstract_t">Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38:1632.</a></li><li><a class="nounderline abstract_t">Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119:931.</a></li><li><a class="nounderline abstract_t">Austin MA, Newman B, Selby JV, et al. Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis. Arterioscler Thromb 1993; 13:687.</a></li><li><a class="nounderline abstract_t">Talmud PJ, Edwards KL, Turner CM, et al. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation 2000; 101:2461.</a></li><li><a class="nounderline abstract_t">Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993; 88:381.</a></li><li><a class="nounderline abstract_t">Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996; 45:1267.</a></li><li><a class="nounderline abstract_t">Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99:1959.</a></li><li><a class="nounderline abstract_t">Santamarina-Fojo S, González-Navarro H, Freeman L, et al. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24:1750.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Brewer HB Jr, Barter PJ, et al. HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nat Rev Cardiol 2018; 15:9.</a></li><li><a class="nounderline abstract_t">Zambon A, Deeb SS, Hokanson JE, et al. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18:1723.</a></li><li><a class="nounderline abstract_t">Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146.</a></li><li><a class="nounderline abstract_t">Zambon A, Deeb SS, Brown BG, et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103:792.</a></li><li><a class="nounderline abstract_t">Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811.</a></li><li><a class="nounderline abstract_t">Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241.</a></li><li><a class="nounderline abstract_t">Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90:67.</a></li><li><a class="nounderline abstract_t">Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955.</a></li><li><a class="nounderline abstract_t">Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875.</a></li><li><a class="nounderline abstract_t">Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.</a></li><li><a class="nounderline abstract_t">St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104:2295.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010; 213:1.</a></li><li><a class="nounderline abstract_t">Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113:20.</a></li><li><a class="nounderline abstract_t">Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477.</a></li><li><a class="nounderline abstract_t">de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298.</a></li><li><a class="nounderline abstract_t">Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350.</a></li><li><a class="nounderline abstract_t">Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998; 39:1263.</a></li><li><a class="nounderline abstract_t">Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32:1741.</a></li><li><a class="nounderline abstract_t">Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000; 102:716.</a></li><li><a class="nounderline abstract_t">Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 1994; 272:305.</a></li></ol></div><div id="topicVersionRevision">Topic 4567 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12957096" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dyslipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534286" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Familial lipoprotein disorders in patients with premature coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591825" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318511" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21539517" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947591" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8429263" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2372896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3418853" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Low-density lipoprotein subclass patterns and risk of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537421" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991056" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1390589" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Familial combined hyperlipidemia and abnormal lipoprotein lipase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7753827" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447257" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged&lt;or = 50 years) and women (&lt;or = 60 years) with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859281" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834528" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31591002" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184285" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9526813" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162940" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15024300" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531308" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067804" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996525" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443147" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623902" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27765764" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783906" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Child-Parent Familial Hypercholesterolemia Screening in Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586733" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931866" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050191" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185134" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Apolipoprotein E in hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7966894" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758960" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878422" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of apolipoprotein E genotypes with lipid levels and coronary risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8031206" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10736278" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326420" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204302" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8485120" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831518" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339401" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : LDL subclass phenotypes and the insulin resistance syndrome in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843183" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208998" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284087" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hepatic lipase, lipoprotein metabolism, and atherogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28795686" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9812910" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901665" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171785" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375431" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8060384" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1799399" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643858" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782636" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782637" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11696468" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451205" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380547" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10662743" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998647" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475928" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643358" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1770294" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942737" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Endothelial dysfunction in men with small LDL particles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8028144" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Low-density lipoprotein density and atherosclerosis. Unraveling the connection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
